1260403-64-2Relevant articles and documents
Enantioselective Access to Chiral Cyclic Sulfamidates Through Iridium-Catalyzed Asymmetric Hydrogenation
Liu, Yuanhua,Huang, Yi,Yi, Zhiyuan,Liu, Gongyi,Dong, Xiu-Qin,Zhang, Xumu
supporting information, p. 1582 - 1586 (2019/02/19)
The Iridium-catalyzed asymmetric hydrogenation of cyclic sulfamidate imines was successfully developed with N-methylated ZhaoPhos L2 as the ligand. A variety of chiral cyclic sulfamidates were obtained with excellent results (up to 99% yield, 99% ee). Furthermore, this asymmetric hydrogenation can be employed as the key reaction step to prepare the important intermediates in organic synthesis. (Figure presented.).
PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST
-
, (2011/02/24)
The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.